No, paclitaxel should NOT be diluted in 1.6% w/v normal saline
Paclitaxel must be diluted only in 0.9% Sodium Chloride Injection, USP (normal saline), 5% Dextrose Injection, USP, 5% Dextrose and 0.9% Sodium Chloride Injection, or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2 mg/mL 1. The FDA-approved drug label explicitly specifies these diluents and does not include 1.6% saline as an acceptable option.
Why This Matters
Using an unapproved diluent concentration poses several critical risks:
Osmolarity concerns: 1.6% saline is hypertonic (approximately 273 mOsm/L vs. 154 mOsm/L for 0.9% NS), which may cause:
- Vein irritation and phlebitis
- Altered drug stability
- Unpredictable precipitation patterns
- Increased risk of infusion site reactions
Lack of stability data: The FDA label and published stability studies only validate paclitaxel in the specified diluents 1, 2, 3. Using 1.6% saline means you're operating without any evidence of chemical or physical stability.
Precipitation risk: Paclitaxel formulations are notoriously prone to precipitation, which is concentration- and diluent-dependent. Studies show precipitation is the limiting factor for paclitaxel stability 3. An untested diluent could trigger immediate or delayed precipitation.
Practical Guidance
If 0.9% NS is unavailable:
- Use 5% Dextrose Injection as the alternative (also FDA-approved) 1
- Do NOT improvise with non-standard saline concentrations
- Contact pharmacy immediately to obtain appropriate diluent
Container requirements remain the same regardless of diluent:
- Use glass, polypropylene, or polyolefin containers (NOT PVC) 1
- Administer through polyethylene-lined tubing
- Use in-line filter ≤0.22 microns 1
Common Pitfall
The temptation to use available supplies when standard diluents are unavailable is understandable but dangerous. Paclitaxel's formulation with Cremophor EL makes it particularly sensitive to preparation variables. Even minor deviations from validated protocols can compromise patient safety through unpredictable drug behavior, increased hypersensitivity reactions, or inadequate dosing due to precipitation 1.
Bottom line: Delay the infusion if necessary to obtain proper 0.9% NS or 5% dextrose. Patient safety requires strict adherence to FDA-approved preparation guidelines.